Next, YBX1 expression was checked on BM‐MSCs treated with various AML sEVs (MV4‐11 and paediatric AML patient) and non‐AML sEVs (paediatric healthy control and K562). This evidence concerns the gene YBX1 and acute myeloid leukemia.